Altria/$MO

1D1W1MYTD1Y5YMAX

About Altria

Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Horizon Innovations, and Helix Innovations. Through its tobacco subsidiaries, Altria maintains the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the US with 40% share in 2025. Beyond its core business, it holds an 8% interest in the world's largest brewer, Anheuser-Busch InBev, and a 41% stake in cannabis manufacturer Cronos. In reduced-risk products, it acquired vaping company Njoy Holdings in 2023, operates a joint venture with Japan Tobacco in the heated tobacco category for the US, and sells the On brand in nicotine pouches.
Ticker
$MO
Primary listing
NYSE
Employees
5,900

Altria Metrics

BasicAdvanced
$115B
14.50
$4.75
0.49
$4.24
6.16%

What the Analysts think about Altria

Analyst ratings (Buy, Hold, Sell) for Altria stock.
Analyst projections of the future price of Altria stock.

Bulls say / Bears say

Altria is still producing steady earnings from its core franchise. First-half adjusted EPS rose 4.9%, smokeable operating income increased, and management raised the bottom of its 2026 adjusted EPS range to $5.61–$5.72. (Altria)
The nicotine-pouch market is expanding quickly, and on! PLUS is giving Altria a credible growth option. The product reached 120,000 stores, while on! improved its quarterly share of the overall oral category by 0.8 percentage points as nicotine pouches approached 60% of that market. (Altria, Altria Group, Inc.)
Altria remains attractive to income investors because it is returning substantial cash while keeping leverage near management’s target. It paid roughly $3.6 billion in dividends and repurchased $335 million of shares in the first half, with debt to EBITDA at 1.9 times. (The Motley Fool, Altria)
The main cash-generating business is still in structural decline. Altria reported lower cigarette shipment volumes and a 1.5 percentage-point year-on-year fall in Marlboro’s overall retail share, leaving pricing and mix to do more work each year. (Altria)
Altria’s smoke-free transition has not yet become a reliable replacement for lost cigarette profit. On! shipments fell 4.2% in the second quarter, its pouch share was down 1.7 percentage points year on year, and management’s 2026 plan assumes NJOY ACE will not return to the market this year. (Altria, Tobacco Insider)
Regulatory execution remains a material risk to future growth. Altria sued the FDA in September, arguing that its slow review process is holding back nicotine-pouch products while unauthorised competitors continue to gain share in the US. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 22 Sept 2026.

Altria Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

Altria Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.